Economic and humanistic burden of post-trauma and post-surgical neuropathic pain among adults in the United States

Bruce Parsons, Caroline Schaefer, Rachael Mann, Alesia Sadosky, Shoshana Daniel, Srinivas Nalamachu, Brett R Stacey, Edward C Nieshoff, Michael Tuchman, Alan Anschel, Bruce Parsons, Caroline Schaefer, Rachael Mann, Alesia Sadosky, Shoshana Daniel, Srinivas Nalamachu, Brett R Stacey, Edward C Nieshoff, Michael Tuchman, Alan Anschel

Abstract

Background: Neuropathic pain (NeP) can be chronic, debilitating, and can interfere with sleep, functioning, and emotional well being. While there are multiple causes of NeP, few studies have examined the disease burden and treatment patterns associated with post-traumatic/post-surgical (PTPS) NeP.

Objective: To characterize pain, health status, function, health care resource utilization, lost productivity, and costs among subjects with PTPS NeP in the United States.

Methods: This observational study enrolled 100 PTPS NeP subjects recruited during routine visits from general practitioner and specialist sites. Subjects completed a one-time questionnaire with validated measures of pain severity and pain interference, health status, sleep, anxiety and depression, productivity, and study-specific items on demographics, employment status, and out-of-pocket expenses. Investigators completed a case report form based on a 6-month retrospective chart review, recording subjects' clinical characteristics as well as current and previous medications/treatments for NeP. Subjects were stratified into mild, moderate, and severe pain groups.

Results: Subjects' demographic characteristics were: mean age of 54.9 years, 53% female, and 22% employed for pay. Mean pain severity score was 5.6 (0-10 scale), with 48% and 35% classified as having moderate and severe pain, respectively. The mean number of comorbidities increased with greater pain severity (P = 0.0009). Patient-reported outcomes were worse among PTPS NeP subjects with more severe pain, including pain interference with function, health state utility, sleep, and depression (P < 0.0001). Eighty-two percent of subjects were prescribed two or more NeP medications. The total mean annualized adjusted direct and indirect costs per subject were $11,846 and $29,617, respectively. Across pain severity levels, differences in annualized adjusted direct and indirect costs were significant (P < 0.0001).

Conclusion: PTPS NeP subjects reported high pain scores, which were associated with poor health utility, sleep, mood, and function, as well as high health care resource utilization and costs. The quality of life impact and costs attributable to PTPS NeP suggest an unmet need for effective and comprehensive management.

Keywords: costs; neuropathic pain; patient-reported outcomes; productivity; quality-of-life; trauma/surgery.

Figures

Figure 1
Figure 1
PTPS NeP subjects reported a variety of comorbid conditions.a Notes: aScores on the BPI-SF Pain Severity Index were used to classify average pain severity. Three subjects did not respond to all required items needed to calculate a BPI-SF average pain severity score, and thus were not included in any analysis by pain severity category; **statistically significant differences were observed across pain severity levels at the P < 0.05 level as follows: depressive symptoms (P = 0.0205), restless leg syndrome (P = 0.0293), and chronic fatigue syndrome (P = 0.0025). Abbreviations: PTPS, post-traumatic/post-surgical; NeP, neuropathic pain; BPI-SF, Brief Pain Inventory-Short Form.
Figure 2
Figure 2
PTPS NeP subjects with more severe pain reported significantly worse physical and mental health.a Notes:aScores on the BPI-SF Pain Severity were used to classify average pain severity. Three subjects did not respond to all required items needed to calculate a BPI-SF average pain severity score and thus were not included in any analysis by pain severity category. SF-12 PCS and MCS both scored on a scale of 0–100; population norms (PCS = 49.7 and MCS = 49.5), indicated by thick black horizontal lines. **Statistically significant differences were observed by pain severity levels at the P < 0.05 level for the PCS (P = 0.0004); ***statistically significant differences were observed by pain severity levels at the P < 0.0001 level for the MCS. Abbreviations: PTPS, post-traumatic/post-surgical; NeP, neuropathic pain; BPI-SF, Brief Pain Inventory-Short Form; PCS, Physical Component Summary; MCS, Mental Component Summary; SF-12, Short-Form Health Survey.
Figure 3
Figure 3
PTPS NeP subjects with more severe pain have significantly worse general health status.a Notes:aScores on the BPI-SF Pain Severity were used to classify average pain severity. Three subjects did not respond to all required items needed to calculate a BPI-SF average pain severity score and thus were not included in any analysis by pain severity category. EQ-5D scored on a scale of 0–1.0; the population norm (0.87) is indicated by black horizontal line. ***A statistically significant difference was observed across pain severity levels for EQ-5D health state utility: P < 0.0001. Abbreviations: PTPS, post-traumatic/post-surgical; NeP, neuropathic pain; BPI-SF, Brief Pain Inventory-Short Form; EQ-5D, EuroQol Five-Dimensions.
Figure 4
Figure 4
PTPS NeP subjects with more severe pain experience, more interference with function.a Notes:aScores on the BPI-SF Pain Severity were used to classify average pain severity. Three subjects did not respond to all required items needed to calculate a BPI-SF average pain severity score and thus were not included in any analysis by pain severity category. BPI-SF Pain Severity Index scored on a 0–10 scale. ***A statistically significant difference was observed across pain severity levels for BPI-SF Pain Interference Index: P < 0.0001. Abbreviations: PTPS, post-traumatic/post-surgical; NeP, neuropathic pain; BPI-SF, Brief Pain Inventory-Short Form.
Figure 5
Figure 5
PTPS NeP subjects with more severe pain reported worse sleep outcomes.a Notes:aScores on the BPI-SF Pain Severity were used to classify average pain severity. Three subjects did not respond to all required items needed to calculate a BPI-SF average pain severity score and thus were not included in any analysis by pain severity category. MOS-SS Sleep Disturbance and Sleep Problems Index are both scored on a scale from 0–100; the MOS-SS Sleep Problems Index population norm (25.8) is indicated by a black horizontal line. ***A statistically significant difference was observed across pain severity levels for the MOS-SS Sleep Disturbance and Sleep Problems Index; both P < 0.0001. Abbreviations: PTPS, post-traumatic/post-surgical; NeP, neuropathic pain; BPI-SF, Brief Pain Inventory-Short Form; MOS-SS, Medical Outcomes Study Sleep Scale.
Figure 6
Figure 6
PTPS NeP subjects with more severe pain experience, more anxiety and depression.a Notes:aScores on the BPI-SF Pain Severity were used to classify average pain severity. Three subjects did not respond to all required items needed to calculate a BPI-SF average pain severity score, and thus were not included in any analysis by pain severity category. Anxiety and depression were scored on a 0–21 scale: normal (0–7), mild (8–10), moderate (11–14), severe (15–21). The difference observed across pain severity levels for HADS Anxiety was not significant at the 0.05 significance level; P = 0.0553. ***A statistically significant difference was observed across pain severity levels for HADS depression: P < 0.0001. Abbreviations: PTPS, post-traumatic/post-surgical; NeP, neuropathic pain; BPI-SF, Brief Pain Inventory-Short Form; HADS, Hospital Anxiety and Depression Scale.
Figure 7
Figure 7
Use of PTPS NeP prescription medications. Notes:aFigure includes all reported classes, except miscellaneous agents, with >2% of subjects prescribed one or more medication(s) in the class; bopioids (all) includes strong short-acting opioids (47.0%), long-acting opioids (31.0%), and weak short-acting opioids (18.0%). Subjects may have been prescribed more than one type of opioids. Abbreviations: PTPS, post-traumatic/post-surgical; NeP, neuropathic pain; SNRI, serotonin–norepineprhine reuptake inhibitor; NSAIDs, nonsteroidal anti-inflammatory drugs; TCAs, tricyclic antidepressants.
Figure 8
Figure 8
PTPS NeP impact on employment status.a,** Notes:aScores on the BPI-SF Pain Severity were used to classify average pain severity. Three subjects did not respond to all required items needed to calculate a BPI-SF average pain severity score, and thus were not included in any analysis by pain severity category. **A statistically significant difference was observed across pain severity levels at the 0.05 level for the impact of PTPS NeP on employment status; P = 0.0002. Abbreviations: PTPS, post-traumatic/post-surgical; NeP, neuropathic pain; BPI-SF, Brief Pain Inventory-Short Form.
Figure 9
Figure 9
PTPS NeP subjects with more severe pain experienced greater losses in productivity.a Notes:aScores on the BPI-SF Pain Severity were used to classify average pain severity. Three subjects did not respond to all required items needed to calculate a BPI-SF average pain severity score and thus were not included in any analysis by pain severity category. WPAI overall work impairment among those employed, and activity impairment among both employed and unemployed scored on a 0%–100% scale. **A statistically significant difference was observed across pain severity levels at the 0.05 level for overall work impairment (P = 0.0026). ***A statistically significant difference was observed across pain severity levels at the <0.0001 level for activity impairment (P < 0.0001). Abbreviations: PTPS, post-traumatic/post-surgical; NeP, neuropathic pain; BPI-SF, Brief Pain Inventory-Short Form; WPAI, Work Productivity and Activity Impairment.
Figure 10
Figure 10
Adjusted average annualized cost per PTPS NeP subject, overall and by average pain severity.a Notes:aScores on the BPI-SF Pain Severity were used to classify average pain severity as follows: 0–3 represents mild pain, 4–6 represents moderate pain, and 7–10 represents severe pain; baverage annualized total direct cost per subject was significantly different by pain severity (P < 0.0001). Direct costs include physician visits, other health care provider visits, prescription medications, TENS device, outpatient tests/procedures, emergency room visits, hospital outpatient visits, hospitalizations, direct medical costs to subjects, and direct nonmedical costs (child care, help with house and/or yard work, and help with activities of daily living) due to PTPS NeP. cAverage annualized total indirect cost per subject was significantly different by pain severity (P < 0.0001). Total indirect costs include overall work impairment, activity impairment, disability, unemployment, early retirement, and reduced work schedule due to PTPS NeP. dAdjusted LS mean estimates from multiple linear regression adjusted for confounding demographic and clinical variables – specifically, covariates for direct costs: ethnicity, pain severity (mild/moderate/severe only), prescription coverage, and comorbidities (headache/migraine, major depressive disorder, irritable bowel syndrome, cognitive dysfunction, chronic fatigue syndrome [overall only], sleep disturbance/insomnia, chronic low back pain, and other); and for indirect costs: age, race, pain severity, and comorbidities (major depressive disorder and irritable bowel syndrome). Abbreviations: PTPS, post-traumatic/post-surgical; NeP, neuropathic pain; BPI-SF, Brief Pain Inventory-Short Form; TENS, transcutaneous electrical nerve stimulation; LS, least squares.

References

    1. International Association for the Study of Pain IASP taxonomy: pain terms [webpage on the Internet] Washington, DC; International Association for the Study of Pain; 2011Available from: Accessed April 8, 2013
    1. Gregg EW, Gu Q, Williams D, et al. Prevalence of lower extremity diseases associated with normal glucose levels, impaired fasting glucose, and diabetes among US adults aged 40 or older. Diabetes Res Clin Pract. 2007;77(3):485–488.
    1. International Association for the Study of Pain Diagnosis and classification of neuropathic pain. International Association for the Study of Pain: Pain Clinical Updates. 2010;18(7):1–6.
    1. National Institute of Neurological Disorders and Stroke Peripheral neuropathy fact sheet [webpage on the Internet] Bethesda, MD: National Institute of Neurological Disorders and Stroke; 2012Available from: Accessed November 26, 2012
    1. Freynhagen R, Bennett MI. Diagnosis and management of neuropathic pain. BMJ. 2009;339:b3002.
    1. Tölle T, Dukes E, Sadosky A. Patient burden of trigeminal neuralgia: results from a cross-sectional survey of health state impairment and treatment patterns in six European countries. Pain Pract. 2006;6(3):153–160.
    1. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005;30(4):374–385.
    1. Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: the patients’ perspectives. J Pain. 2006;7(12):892–900.
    1. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology. 2007;68(15):1178–1182.
    1. Sadosky A, Schaefer C, Mann R, et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey. Diabetes Metab Syndr Obes. 2013;6:79–92.
    1. Jensen MP, Smith DG, Ehde DM, Robinson LR. Pain site and the effects of amputation pain: further clarification of the meaning of mild, moderate, and severe pain. Pain. 2001;91(3):317–322.
    1. Macdonald L, Bruce J, Scott NW, Smith WC, Chambers WA. Long-term follow-up of breast cancer survivors with post-mastectomy pain syndrome. Br J Cancer. 2005;92(2):225–230.
    1. van der Schans CP, Geertzen JH, Schoppen T, Dijkstra PU. Phantom pain and health-related quality of life in lower limb amputees. J Pain Symptom Manage. 2002;24(4):429–436.
    1. Dworkin RH, Panarites CJ, Armstrong EP, Malone DC, Pham SV. Healthcare utilization in people with postherpetic neuralgia and painful diabetic peripheral neuropathy. J Am Geriatr Soc. 2011;59(5):827–836.
    1. daCosta DiBonaventura M, Cappelleri JC, Joshi AV. A longitudinal assessment of painful diabetic peripheral neuropathy on health status, productivity, and health care utilization and cost. Pain Med. 2011;12(1):118–126.
    1. Mehra M, Hill K, Nicholl D, Schadrack J. The burden of chronic low back pain with and without a neuropathic component: a healthcare resource use and cost analysis. J Med Econ. 2012;15(2):245–252.
    1. Declaration of Helsinki Adopted by the 18th World Medical Assembly (WMA) General Assembly H, Finland, 1964; amended by the 29th WMA General Assembly in Tokyo, Japan in 1975, the 35th WMA General Assembly in Venice, Italy in 1983, the 41st WMA General Assembly in Hong Kong in 1989, the 48th WMA General Assembly in Somerset West, Republic of South Africa in 1996, and the 52nd WMA General Assembly in Edinburgh, Scotland. 2000.
    1. Pharmacy Benefit Management Institute, LP Pharmacy and drug manufacturer reimbursement [webpage on the Internet] Plano, TX: Pharmacy and Benefit Management Institute, LP; 2012Available from: Accessed April, 23, 2012
    1. US Bureau of Labor Statistics May 2010 National Occupational Employment and Wage Estimates [website on the Internet] Washington, DC: United States Department of Labor, Bureau of Labor Statistics; Available from: Accessed April 25, 2012
    1. Lofland JH, Pizzi L, Frick KD. A review of health-related workplace productivity loss instruments. Pharmacoeconomics. 2004;22(3):165–184.
    1. US Social Security Administration Annual Statistical Supplement 2011Table 5.D1 [webpage on the Internet]. Available from: Accessed April 23, 2012
    1. Zelman DC, Dukes E, Brandenburg N, Bostrom A, Gore M. Classification of mild, moderate and severe pain due to diabetic peripheral neuropathy based on levels of functional disability. J Pain. 2004;5(Suppl 1):114.
    1. Zelman DC, Dukes E, Brandenburg N, Bostrom A, Gore M. Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. Pain. 2005 May;115(1–2):29–36.
    1. Ware JE, KM Turner-Bowker, DM Sundaram M, Gandek B, Maruish ME. User’s Manual for the SF-12v2 Health Survey Second Edition. QualityMetric, Incorporated. 2009
    1. Luo N, Johnson JA, Shaw JW, Feeny D, Coons SJ. Self-reported health status of the general adult US population as assessed by the EQ-5D and Health Utilities Index. Med Care. 2005;43(11):1078–1086.
    1. Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the Medical Outcomes Study Sleep Scale measure. Sleep Med. 2005;6(1):41–44.
    1. Attal N, Cruccu G, Baron R, et al. European Federation of Neurological Societies EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):e1113–e1188.
    1. Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237–251.
    1. Dworkin R, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(Suppl 3):S3–S14.
    1. Whyte AS, Carroll LJ. A preliminary examination of the relationship between employment, pain and disability in an amputee population. Disabil Rehabil. 2002;24(9):462–470.
    1. Ehde DM, Czerniecki JM, Smith GD, et al. Chronic phantom sensations, phantom pain, residual limb pain, and other regional pain after lower limb amputation. Arch Phys Med Rehabil. 2000;81(8):1039–1044.
    1. Macrae WA. Chronic post-surgical pain: 10 years on. Br J Anaesth. 2008;101(1):77–86.
    1. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory-Short Form. Ann Acad Med Singapore. 1994;23(2):129–138.
    1. Ware J, Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–233.
    1. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–343.
    1. Snaith RP, Zigmond AS. The hospital anxiety and depression scale. Br Med J (Clin Res Ed) 1986;292(6516):344.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370.
    1. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–365.

Source: PubMed

3
Abonner